Skip to main content

Table 1 Groups’ demographic characterization and overview of the clinical data of the Parkinson’s disease group used for the discovery study

From: A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson’s disease potential biomarkers

 Age at blood coll. (y)aGenderbDisease Duration (y)Age at Onset (y)Family historycHY scaledTotal L-Dopa (converted CR + IR) (mg/day)e
Parkinson's Disease Group74 ± 7 [63, 83]M:17 (54.8%); F: 14 (45.2%)6.2 ± 3.8 [0.7, 15]67.7 ± 7.4 [48, 80]N: 30; Y:11.8 ± 1 [1, 4]374.7 ± 288.7 [0, 1150]
Control Group67 ± 10 [55, 83]M: 16 (57.1%) F: 12 (42.9%)
  1. aAge at blood coll. (y): age at blood collection in years
  2. bThe individuals were divided into males (M) and females (F)
  3. cNumber of individuals with familiar history of PD (Y) and those without any familiar link to the disease (N)
  4. dHoehn and Yahr scale
  5. eTotal L-Dopa (converted CR + IR) (mg/day): calculated as the controlled release (CR) plus immediate-release (IR) in milligrams per day